DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Crestor (Rosuvastatin Calcium) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in other sections of the label:

  • Rhabdomyolysis with myoglobinuria and acute renal failure and myopathy (including myositis) [see ] • Warnings and Precautions
  • Liver enzyme abnormalities [see ] • Warnings and Precautions

In the CRESTOR controlled clinical trials database (placebo or active-controlled) of 5394 patients with a mean treatment duration of 15 weeks, 1.4% of patients discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were:

  • myalgia •
  • abdominal pain •
  • nausea •

The most commonly reported adverse reactions (incidence ≥ 2%) in the CRESTOR controlled clinical trial database of 5394 patients were:

  • headache •
  • myalgia •
  • abdominal pain •
  • asthenia •
  • nausea •

Clinical Studies Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.

Adverse reactions reported in ≥ 2% of patients in placebo-controlled clinical studies and at a rate greater than placebo are shown in Table 1. These studies had a treatment duration of up to 12 weeks.

  • Table. Adverse Reactions Reported in ≥ 2% of Patients Treated with CRESTOR and > Placebo in Placebo‑Controlled Trials (% of Patients)   1

Adverse Reactions

CRESTOR

5 mg

N=291

CRESTOR

10 mg

N=283

CRESTOR

20 mg

N=64

CRESTOR

40 mg

N=106

Total CRESTOR

5 mg‑40 mg

N=744

Placebo

N=382

Headache

5.5

4.9

3.1

8.5

5.5

5.0

Nausea

3.8

3.5

6.3

0

3.4

3.1

Myalgia

3.1

2.1

6.3

1.9

2.8

1.3

Asthenia

2.4

3.2

4.7

0.9

2.7

2.6

Constipation

2.1

2.1

4.7

2.8

2.4

2.4

Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity (including rash, pruritus, urticaria, and angioedema) and pancreatitis. The following laboratory abnormalities have also been reported: dipstick-positive proteinuria and microscopic hematuria [see ]; elevated creatine phosphokinase, transaminases, glucose, glutamyl transpeptidase, alkaline phosphatase, and bilirubin; and thyroid function abnormalities. Warnings and Precautions

In the METEOR study, involving 981 participants treated with rosuvastatin 40 mg (n=700) or placebo (n=281) with a mean treatment duration of 1.7 years, 5.6% of subjects treated with CRESTOR versus 2.8% of placebo-treated subjects discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were: myalgia, hepatic enzyme increased, headache, and nausea [see ]. Clinical Studies

Adverse reactions reported in ≥ 2% of patients and at a rate greater than placebo are shown in Table 2.

  • Table. Adverse Reactions Reported in ≥2% of Patients Treated with CRESTOR and > Placebo in the METEOR Trial (% of Patients)   1
Adverse Reactions CRESTOR 40 mg
N=700
Placebo
N=281

Myalgia

12.7

12.1

Arthralgia

10.1

7.1

Headache

6.4

5.3

Dizziness

4.0

2.8

Increased CPK

2.6

0.7

Abdominal pain

2.4

1.8

ALT >3x ULN 1

2.2

0.7

1 Frequency recorded as abnormal laboratory value.

In the JUPITER study, 17,802 participants were treated with rosuvastatin 20 mg (n=8901) or placebo (n=8901) for a mean duration of 2 years. A higher percentage of rosuvastatin-treated patients versus placebo-treated patients, 6.6% and 6.2%, respectively, discontinued study medication due to an adverse event, irrespective of treatment causality. Myalgia was the most common adverse reaction that led to treatment discontinuation.

In JUPITER, there was a significantly higher frequency of diabetes mellitus reported in patients taking rosuvastatin (2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in rosuvastatin-treated patients compared to placebo-treated patients. The number of patients with a HbA1c > 6.5% at the end of the trial was significantly higher in rosuvastatin-treated versus placebo-treated patients [see and ]. Warnings and Precautions Clinical Studies

Adverse reactions reported in ≥ 2% of patients and at a rate greater than placebo are shown in Table 3.

  • Table. Adverse Reactions Reported in ≥ 2% of Patients Treated with CRESTOR and > Placebo in the JUPITER Trial (% of Patients)   1

Adverse Reactions

CRESTOR 20 mg

N=8901

Placebo

N=8901

Myalgia

7.6

6.6

Arthralgia

3.8

3.2

Constipation

3.3

3.0

Diabetes mellitus

2.8

2.3

Nausea

2.4

2.3

Pediatric patients 10 to 17 years of age

In a 12-week controlled study in boys and postmenarchal girls, the safety and tolerability profile of CRESTOR 5 to 20 mg daily was generally similar to that of placebo [see and ]. Clinical Studies Use in Specific Populations, Pediatric Use

However, elevations in serum creatine phosphokinase (CK) > 10 x ULN were observed more frequently in rosuvastatin compared with placebo-treated children. Four of 130 (3%) children treated with rosuvastatin (2 treated with 10 mg and 2 treated with 20 mg) had increased CK >10 x ULN, compared to 0 of 46 children on placebo.

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of CRESTOR: arthralgia, fatal and non-fatal hepatic failure, hepatitis, jaundice, thrombocytopenia, depression, sleep disorders (including insomnia and nightmares), peripheral neuropathy and gynecomastia. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see ]. Warnings and Precautions

There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).



REPORTS OF SUSPECTED CRESTOR SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Crestor. The information is not vetted and should not be considered as verified clinical evidence.

Possible Crestor side effects / adverse reactions in 63 year old female

Reported by a physician from Spain on 2011-10-03

Patient: 63 year old female

Reactions: Photosensitivity Reaction, Urticaria Papular

Suspect drug(s):
Crestor
    Administration route: Oral
    Start date: 2010-12-01
    End date: 2011-03-01

Hydrochlorothiazide
    Administration route: Oral
    Start date: 2010-12-01
    End date: 2011-03-01

Multaq
    Administration route: Oral
    Indication: Atrial Fibrillation
    Start date: 2011-01-01
    End date: 2011-03-01

Doxylamine Succinate
    Administration route: Oral
    End date: 2011-09-01

Other drugs received by patient: Sintrom; Omeprazole



Possible Crestor side effects / adverse reactions in 77 year old male

Reported by a consumer/non-health professional from United States on 2011-10-03

Patient: 77 year old male

Reactions: Memory Impairment, Convulsion

Suspect drug(s):
Crestor

Other drugs received by patient: Dilantin



Possible Crestor side effects / adverse reactions in 84 year old male

Reported by a consumer/non-health professional from Brazil on 2011-10-03

Patient: 84 year old male weighing 76.0 kg (167.2 pounds)

Reactions: Labyrinthitis

Adverse event resulted in: hospitalization

Suspect drug(s):
Crestor
    Administration route: Oral
    Start date: 2011-09-01

Crestor
    Administration route: Oral
    Indication: Hypercholesterolaemia
    Start date: 2011-08-23
    End date: 2011-09-01

Other drugs received by patient: Stugeron; Dramin B6; Taxotere; Coumadin; Coumadin



See index of all Crestor side effect reports >>

Drug label data at the top of this Page last updated: 2014-07-08

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017